Dengue Program

About Integrated Research Associates

Integrated Research Associates, founded in 2007, is a private biotechnology company operating in both therapeutic development and research reagents. Its core mission is to address unmet medical needs posed by neurovirulent and globally spreading viruses like dengue, Zika, and Japanese encephalitis through drug and vaccine R&D. The company has a dual business model, combining early-stage, pre-clinical therapeutic programs with a commercial portfolio of validated viral antigens and antibodies for the research community. This provides a revenue stream while funding its internal development efforts.

About ExeVir

ExeVir is a private, clinical-stage biotech leveraging a proprietary VHH (single-domain antibody) platform to develop multi-specific antibody therapies against infectious diseases. The company has demonstrated rapid development capabilities, advancing its first candidate from research to clinical trials in under a year. Backed by a strong international investor syndicate and strategic research partnerships, ExeVir is building a pipeline initially targeting COVID-19 and dengue, with the platform holding promise for broader applications in immunology and oncology.

Therapeutic Areas